By Joel Hesch, Liberty University
The government has honed in on three primary areas where it alleges that a pharmaceutical company commits fraud. In addition, there is an emerging new area, adulterated products, where the DOJ is beginning to investigate and just may be the next huge compliance risk.
September 30, 2009
March 12, 2010
March 10, 2010
March 1, 2010
February 25, 2010
February 24, 2010
March 2, 2010
February 18, 2010
February 16, 2010
March 12, 2010
March 10, 2010
March 10, 2010
January 18, 2010
January 12, 2010
March 10, 2010
March 4, 2010
March 1, 2010
February 25, 2010
February 18, 2010
February 11, 2010
February 17, 2010
February 18, 2010
February 15, 2010
February 11, 2010
March 10, 2010
March 7, 2010
March 1, 2010
February 1, 2010
The "Massive News" theme by: Press75.com
|
Home |
About |
Contact |
Authors |
Write for CCI |
Article Guildelines |
Compliance News |
People on the Move |
Legal Notice |
Privacy Policy |
Corporate Compliance Insights is a professionally designed and managed forum dedicated to online discussion and analysis of corporate compliance and governance topics. Additionally, Corporate Compliance Insights is a focused knowledge-sharing forum designed to educate and encourage informed interaction within the corporate compliance community.
Helpful resources:
NCAA tournament schedule, March Madness 2010 tickets
